Novopyxis leverages advanced mathematical and physical principles to innovate in drug design and delivery. Their team, composed of MIT-trained scientists, employs ab initio mathematics and knot theory to develop proprietary algorithms that facilitate protein structure generation. This approach addresses a significant challenge in drug design, particularly the lack of crystal structures for target proteins. By utilizing machine learning, Novopyxis can predict the structures of uncrystallized proteins and design peptide agonists, exemplified by their flagship drug, NP-6A, which selectively activates the Angiotensin II Type 2 Receptor (AT2R) and has shown efficacy in various biological models.

In addition to their therapeutic advancements, Novopyxis has developed a novel transdermal delivery system called Droplette. This patent-pending device is capable of delivering drugs that are up to 60% larger than those currently available, penetrating deeply into the skin without the need for needles. The Droplette system is designed to be painless, contact-free, and portable, generating no disposables, which enhances its usability in clinical settings. The development of this device was informed by clinician input, ensuring that it meets the practical needs of healthcare providers while improving patient experience.

United States

Novopyxis is a biotechnology company that specializes in the development of therapeutics and medical devices using proprietary mathematical algorithms for drug validation across various models.

Novopyxis

Company Details